--- title: "Everest Medicines Publishes Audited 2025 Annual Results and Report" type: "News" locale: "en" url: "https://longbridge.com/en/news/280545353.md" description: "Everest Medicines Ltd. has published its audited annual results for the year ending December 31, 2025. The full report is available in Chinese and English, with printed copies to be sent to shareholders by April 2026. The results were reviewed by Ernst & Young and comply with Hong Kong listing rules. The current analyst rating for Everest Medicines (HK:1952) is a Hold, with a price target of HK$36.00. The company focuses on developing innovative biopharmaceuticals and has a market cap of HK$12.47B." datetime: "2026-03-25T23:07:27.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280545353.md) - [en](https://longbridge.com/en/news/280545353.md) - [zh-HK](https://longbridge.com/zh-HK/news/280545353.md) --- # Everest Medicines Publishes Audited 2025 Annual Results and Report ### Claim 30% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Everest Medicines Ltd. ( (HK:1952) ) has issued an announcement. Everest Medicines Limited has released its audited annual results for the year ended 31 December 2025, confirming that the full 2025 annual report is now available in both Chinese and English. The results, reviewed by the audit committee and Ernst & Young, will be accessible online, with printed reports delivered to shareholders and electronic versions posted by the end of April 2026, reinforcing the company’s compliance and transparency obligations under Hong Kong listing rules. The most recent analyst rating on (HK:1952) stock is a Hold with a HK$36.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page. **More about Everest Medicines Ltd.** Everest Medicines Limited is a biopharmaceutical company listed on the Hong Kong Stock Exchange, focusing on the development and commercialization of innovative medicines. The group operates through a network of subsidiaries and is overseen by a board comprising executive, non-executive and independent non-executive directors based in Hong Kong and the Cayman Islands. **Average Trading Volume:** 3,174,542 **Technical Sentiment Signal:** Sell **Current Market Cap:** HK$12.47B For an in-depth examination of 1952 stock, go to TipRanks’ Overview page. ### Related Stocks - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [01952.HK](https://longbridge.com/en/quote/01952.HK.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [159570.CN](https://longbridge.com/en/quote/159570.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [159567.CN](https://longbridge.com/en/quote/159567.CN.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) ## Related News & Research - [11:14 ETRibo y Boehringer Ingelheim siguen avanzando en su programa de siRNA](https://longbridge.com/en/news/285402650.md) - [Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation | ONNVF Stock News](https://longbridge.com/en/news/285274936.md) - [Grand Pharmaceutical Moves to Adopt New Bye-Laws Aligned With HK Paperless Regime](https://longbridge.com/en/news/284576690.md) - [Hengrui Pharma Sets Formal Remuneration and Evaluation Committee to Bolster Governance](https://longbridge.com/en/news/284607220.md) - [07:55 ETSupport Egg Quality and Ovulation with Nature's Bounty® New Fertility Supplement*](https://longbridge.com/en/news/285200796.md)